Kentaro Iwata

Kentaro Iwata is a notable inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of four patents. His work focuses on improving the solubility of organic compounds, which is crucial for the development of effective medications.

Latest Patents

Iwata's latest patents include a cocrystal aimed at enhancing the solubility of an organic compound. This cocrystal consists of two components: (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid. Another significant patent involves crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate. This patent details processes for preparing these crystalline forms and their applications in treating cell division cycle 7 mediated cancer in mammals.

Career Highlights

Kentaro Iwata is currently associated with Takeda Pharmaceutical Company Limited, a leading global pharmaceutical company. His work at Takeda has allowed him to focus on innovative solutions that address critical health challenges. His contributions have been instrumental in advancing pharmaceutical research and development.

Collaborations

Iwata has collaborated with esteemed colleagues such as Yukihiro Ikeda and Masahiro Mizuno. These partnerships have fostered a collaborative environment that enhances the innovation process within the pharmaceutical sector.

Conclusion

Kentaro Iwata's work exemplifies the impact of innovation in pharmaceutical chemistry. His patents and collaborations contribute significantly to the advancement of medical science and the development of effective treatments.

This text is generated by artificial intelligence and may not be accurate.